28,327 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Acquired by Amundi

Amundi acquired a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 28,327 shares of the biopharmaceutical company’s stock, valued at approximately $166,000.

Several other large investors have also added to or reduced their stakes in SAGE. Quest Partners LLC lifted its holdings in Sage Therapeutics by 56.3% during the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 6,618 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Sage Therapeutics during the third quarter valued at approximately $473,000. Intech Investment Management LLC purchased a new position in Sage Therapeutics during the third quarter valued at approximately $146,000. Charles Schwab Investment Management Inc. lifted its holdings in Sage Therapeutics by 10.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after purchasing an additional 43,617 shares in the last quarter. Finally, Algert Global LLC lifted its holdings in Sage Therapeutics by 120.6% during the third quarter. Algert Global LLC now owns 143,034 shares of the biopharmaceutical company’s stock valued at $1,033,000 after purchasing an additional 78,190 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $8.10 on Friday. The company’s fifty day moving average is $7.36 and its 200 day moving average is $6.71. Sage Therapeutics, Inc. has a fifty-two week low of $4.62 and a fifty-two week high of $20.32. The stock has a market capitalization of $498.00 million, a PE ratio of -1.23 and a beta of 0.82.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, research analysts forecast that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Stifel Nicolaus lowered their price target on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a report on Monday, December 16th. Wedbush reiterated a “neutral” rating and set a $6.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Bank of America began coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price objective on the stock. Finally, Scotiabank reduced their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.81.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.